

Prof. Dr. med. Peter P. Nawroth



University Hospital Heidelberg,
Department of Medicine I and Clinical Chemistry
University: Heidelberg
Heidelberg, Im Neuenheimer Feld 410

Phone: 06221-568600
Fax: 06221-565226
E-mail: Peter.Nawroth@med.uni-heidelberg.de

Date of birth: 27.10.1954, **City of birth:** Virum/Copenhagen, Denmark

Position: Chair and Director of the Department of Medicine I at the University of Heidelberg.

The Department has its focus on Endocrinology and Metabolism and includes 3 sections:

1. Osteology,
2. Nephrology and
3. Laboratory Medicine.

SCIENTIFIC VITA

1980-1981	Dept. Med. Univ. Tübingen
1982-1985	Dept. Med., Columbia University, New York
1984	Post Doctoral Research Scientist
1985	Associate Research Scientist
1985-1987	Oklahoma Medical Research Foundation
1986-1987	Assistant member OMRF
1987-1999	Dept. Med. I, Univ. Heidelberg, Germany
1991	Board Internal Medicine
1992	Habilitation
1993	Heisenberg-Stipend
1995	Board Angiology
1996	Board Endocrinology and Diabetes
1997	C3-Professorship of the "Schilling-Foundation"
2000	C3-full Professorship Univ. Tübingen, Director of the Section "Vascular Medicine"
2001	Board Laboratory Medicine
2001	Chair and C4-Professor, Dept. Medicine I, Univ. Heidelberg
2004	Centralization of the Laboratory Medicine at the Medical School Heidelberg Supervisor of the central laboratory and special analytical laboratories
2006	Head of the Department Internal Medicine I (Endocrinology and Metabolism, Osteology, Nephrology) and Laboratory Medicine

AWARDS

Various stipends; Member of the German Academy of Sciences Leopoldina
Doctor honoris Causa of Riga Stradins University

COORDINATING FUNCTIONS

2002	Member of the research council of the Univ. Heidelberg
2005	Congress President: Annual Meeting of the German Society for Thrombosis and Hemostasis (GTH) in Mannheim, Germany
2006	Member of the Faculty Board of Sciences, Univ. Heidelberg

2007	Congress President: Annual meeting of the „Deutsche Diabetes Gesellschaft“ (DDG)
2007	Deputy to the Chairman of the Medical School Board, University of Heidelberg
2008, 2009, 2010	Juror „Deutscher Präventionspreis“
2008	Founder and President of the „Juvenile Diabetes Research Foundation Germany“(JDRF)
2010	Section Organizer, Gordon’s Conference 2010
Since 2005:	Editor: “Experimental and Clinical Endocrinology and Diabetes (ECED)”

FIELDS OF INTEREST

Internal Medicine, Clinical and experimental diabetes, Vascular biology, Tumor Biology

FUNDED PROJECTS

Various DFG-grants and SFB initiatives

SFB 405 (funded until June 2009): Immune *Tolerance and its Disturbances*, TP B8: *RAGE and its ligands in immune tolerance and its disruption*

JDRF grant (funded until Aug 2009): Project 2: *RAGE; ROS and NFκB: A Model for understanding the basis of hyperglycemic memory*

BMBF (OGIT 01.01.10-31.12.13): *Obesity and Gastrointestinal Tract – TP 4*

BMBF (Start-up) Excellence cluster: *Bridging Cardiovascular Diseases and Cancer*

PUBLICATIONS (10 selected publications of 455)

1. Bierhaus A, Stoyanov S, Fleming Th, Sauer SK, Leffler A, Babes A, Kichko TI, Neascu C, Konrade I, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornlley PJ, Edelstein D, nau C, Forbes J, Stern DM, Cooper ME, Humpert PM, Brownlee M, Reeh PW, **Nawroth PP**. Methylglyoxal modification of Na_v1.8 facilitates nociceptive neuron firing and causes metabolic hyperalgesia. *In revision*, **2010**
2. Müller-Stich BP, Senft JD, Warschkow R, Kenngott HG, Billeter AT, Vit G, Helfert S, Diener MK, Fischer L, Büchler MW, **Nawroth PP**. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. *Ann Surg*. **2015** Mar;261(3):421-9.
3. Stumvoll M, **Nawroth PP**: The insulin glargine dilemma: an opportunity for the diabetes community. *Diabetologia* 52: 1987-1989, **2009**
4. Kender Z, Fleming T, Kopf S, Torzsa P, Grolmusz V, Herzig S, Schleicher E, Rácz K, Reismann P, **Nawroth PP**. Effect of metformin on methylglyoxal metabolism in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes*. **2014** May;122(5):316-9.
5. Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, Oikomonou D, Ibrahim Y, Pfisterer F, Aydin D, Ahmed N, Thornalley PJ, Sayed AMR, Fleming T, Humpert PM, Schwenger V, Zeier M, Hamann A, Stern DM, Brownlee M, Bierhaus A, **Nawroth PP**,

Morcos M: *C. elegans* as model for the study of high glucose mediated lifespan reduction. **Diabetes**, 58: 2450-6, **2009**

6. Morcos M, Du X, Pfisterer F, Hutter H, Sayed AAR, Thornalley P, Ahmed N, Baynes J, Thorpe S, Kukudov G, Schlotterer A, Abd el Baki R, Stern DM, Möhrle F, Hamann A, Becker Ch, Zeier M, Schwenger V, Bozorgmehr F, Miftari N, Humpert PM, Hammes HP, Büchler MW, Bierhaus A, Brownlee M, **Nawroth PP**: Glyoxalase-1 prevents mitochondrial protein modification and enhances life-span in *C. elegans*. **Aging Cell** 7: 260-269, **2008**
7. Hidmark A, Fleming T, Vittas S, Mendler M, Deshpande D, Groener JB, Müller BP, Reeh PW, Sauer SK, Pham M, Muckenthaler MU, Bendszus M, **Nawroth PP**. A new paradigm to understand and treat diabetic neuropathy. *Exp Clin Endocrinol Diabetes*. **2014** Apr;122(4):201-7.
8. Isermann B, Vinnikov I, Madhusudhan T, Herzog SUE, Kashif M, Blautzik J, Corat MAF, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinell BW, Chavakis T, Esmon C, Weiler H, Bierhaus A, **Nawroth PP**: Activated protein C protects against nephropathy by inhibiting glucose induced endothelial and podocyte apoptosis. **Nat Med**, 13: 1349-58, **2007**
9. Nowotny B, Zahiragic L, Bierwagen A, Kabisch S, Groener JB, Nowotny PJ, Fleitmann AK, Herder C, Pacini G, Erlund I, Landberg R, Haering HU, Pfeiffer AF, **Nawroth PP**, Roden M. Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial. **Diabetologia**. **2015** Feb;58(2):255-64
10. Kopf S, Oikonomou D, Hartmann M, Feier F, Faude-Lang V, Morcos M, Häring HU, Herzog W, Bierhaus A, Humpert PM, **Nawroth PP**. Effects of stress reduction on cardiovascular risk factors in type 2 diabetes patients with early kidney disease - results of a randomized controlled trial (HEIDIS). **Exp Clin Endocrinol Diabetes**. **2014** Jun;122(6):341-9.